Hartman Institute for Therapeutic Organ Regeneration
Rafii Shahin

Shahin Rafii, M.D.

A Message From the Director

“We are witnessing the birth of a new field of cellular therapeutics to build replacement ‘mini-organs’ that have tremendous potential for curing disease relieving human suffering.”

Every year millions of patients worldwide succumb to organ failure, who could have otherwise been cured with tissue replacement therapies. While organ transplantation has been available for many decades, it will never be the solution we had hoped for due to a lack of donor-derived organ availability. Furthermore, the cost of managing patients with organ damage, including cardiovascular, lung, liver, kidney, diabetes, Alzheimer’s, Parkinson’s, and post-COVID-19 maladies is in trillions of dollars. Therefore, there is an urgent need to develop effective therapies to mitigate the plight of patients suffering from terminal organ diseases.

Under the stewardship of Dr. Augustine Choi, Weill Cornell Medicine is well-positioned to expand the frontiers of regenerative medicine and pharmaceuticals to the clinic, by establishing the Hartman Institute for Therapeutic Organ Regeneration. This initiative is timely and will lead to discoveries for the treatment of disorders that afflict millions of people worldwide. The recent pandemic was a wake-up call underscoring the revelation that valid scientific evidence and breakthroughs could save humanity and improve the well-being of everyone of different nationalities and ethnic backgrounds.

Thanks to the pioneers at Weill Cornell Medicine (WCM), scientists have already devised patented breakthroughs and innovated game-changing technologies to fully realize the promise of tissue-specific organoids for repairing injured and malfunctioning organs

Drug Screen Points Toward Novel Diabetes Treatments

A drug currently in clinical trials as a cancer therapy can also stimulate pancreatic beta cells to secrete insulin, revealing a previously unknown mechanism for insulin regulation in type 2 diabetes, according to a new study by Weill Cornell Medicine investigators. The preclinical discovery, reported Nov.

Large-Scale Study Reveals New Genetic Details of Diabetes

In experiments of unprecedented scale, investigators at Weill Cornell Medicine and the National Institutes of Health have revealed new aspects of the complex genetics behind Type 2 diabetes. Through these discoveries, and by providing a template for future studies, this research furthers efforts to better understand, and ultimately, treat this common metabolic disease.

Scientists Pitch Medical Innovations at 2023 Biomedical Business Plan Challenge

Standing on the stage at Uris Auditorium on June 1, Dr. Joe Zhou, an associate professor in regenerative medicine in medicine at Weill Cornell Medicine, made the case for the necessity of developing new approaches to treat diabetes, a disease he called “a true epidemic of the modern world.”

There are no events scheduled at this time.